NATHALIA DA SILVA HALLEY NEVES

Índice h a partir de 2011
2
Projetos de Pesquisa
Unidades Organizacionais
P ICR, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/36 - Laboratório de Pediatria Clínica, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 10 de 11
  • article 2 Citação(ões) na Scopus
    Involvement of the central nervous system in neuroblastomas: A potential direct pathway
    (2020) ODONE-FILHO, Vicente; CRISTOFANI, Lilian Maria; MALUF, Paulo Taufi; ALMEIDA, Maria Tereza Assis; HALLEY, Nathalia; VINCE, Carolina Sgarioni Camargo; AZAMBUJA, Alessandra Milani Prandini de; BRUMATTI, Melina; LUBRAICO, Priscilla; LOPES, Luiz Heraldo Arouche da Camara; LEITE, Katia Ramos Moreira; SILVA, Joao Luis Fernandes; PLESE, Jose Pindaro Pereira; WELTMAN, Eduardo
    Although frequently disseminated to other anatomical sites, neuroblastoma (NB) is rarely reported as involving the central nervous system (CNS), which may reflect insufficient research in poorly controlled systemic disease. Here we demonstrate the involvement of the CNS in patients with NB over 18 months of age at diagnosis of extensive systemic disease. Meningeal metastases were observed even in the presence of complete systemic control. Although no improvement in patient's survival was observed, radiotherapy was effective in preventing CNS recurrence after observation of actual or previous dural disease. In conclusion, this study uncovered the uncommon pathologic involvement of the CNS in children with advanced NB and underscores the meningeal surface as a potential pathway for this to occur.
  • conferenceObject
    MEG3 and MEG8 aberrant methylation associated with worst prognosis in an infant with neuroblastoma
    (2020) NOVAK, Estela M.; GIMENEZ, Thamiris Magalhaes; NEVES, Nathalia Halley; VINCE, Carolina Sgarioni Camargo; KREPISCHI, Ana Cristina Victorino; LAPA, Rainer Marco Lopez; CRISTOFANI, Lilian M.; BENDIT, Israel; ODONE FILHO, Vicente
  • article 2 Citação(ões) na Scopus
    MEG3 and MEG8 aberrant methylation in an infant with neuroblastoma
    (2020) NOVAK, Estela M.; GIMENEZ, Thamiris M.; NEVES, Nathalia H.; VINCE, Carolina C.; KREPISCHI, Ana Cristina V.; LAPA, Rainer M.; CRISTOFANI, Lilian M.; BENDIT, Israel; FILHO, Vicente Odone
  • conferenceObject
    LONG TERM COMPLICATIONS IN CHILDREN TREATED FOR ADVANCED NEUROBLASTOMA
    (2012) HALLEY, Nathalia; CRISTOFANI, Lilian Maria; ALMEIDA, Maria Teresa Assis; MALUF-JUNIOR, Paulo Taufi; CORNACCHIONI, Ana Lucia Beltrati; TEIXEIRA, Roberto Augusto Plaza; ZAMPERLINI-NETO, Gabriele; GOMES, Alessandra Araujo; ODONE-FILHO, Vicente
    Purpose: Advanced neuroblastoma (stage 3 and 4) requires aggressive treatment, including surgery, chemo and radiotherapy and autologous bone marrow transplantation. Although long term survival rates are disappointing, those children who survive are prone to develop long term complications. Our aim is to report the long term complications rate and quality in children treated for stage 3 and 4 neuroblastoma. Methods: The charts of stage 3 and 4 children with neuroblastoma treated from January/1983 through October/2003 were reviewed and those surviving and with no evidence of disease for more than 5 years were selected. Late effects were classified as second malignancies, endocrinological, neuromotor, hepatic, sensorial, benign tumors, infectious diseases and psychiatric disease and others. Associations with treatment modalities were disclosed. Results: Among 263 children with stage 3 and 4 neuroblastoma, 40 (15%) are long term survivors. 20/40 (50%) present one or more complications, being 2 (10%) second malignant neoplasia, 4 (20%) endocrinological disturbances, 4 (20%) neuromotor, 5 (25%) hepatic, 4 (20%) sensorial, 3 (1.1%) benign tumors, and infertility, psychiatric disease and hepatitis C infection in 1 (5%) episode each. 10/20 (50%) of the children were less than 18 months at diagnosis, and 12/20 (60%) were stage 3 and 8/20 (40%) were stage 4. All children were submitted to chemotherapy and 7/20 (35%) to autologous bone marrow transplantation. In 10/20 (50%) patients radiotherapy was also included, and 4/10 (40%) presented functional lesions in the irradiated field. All endocrinologic sequelae were detected in the ABMT group. Second malignant neoplasia were not related to RDT(1 ALL and 1 thyroid carcinoma). Conclusion: Children surviving aggressive therapy for neuroblastoma are at risk of late effects, particularly endocrinological and neurological complications, requiring close observation to prompt intervention when necessary, avoiding impairments in quality of life or even life threatening situations. Second malignant neoplasia require special concern.
  • conferenceObject
    Identification Somatic Variants FOXO3A and FOXK2 in Neuroblastoma Patients that May Affect Doxorubicin and Platin Chemoterapy
    (2018) ODONE-FILHO, V.; NEVES, N. H.; GIMENEZ, T. M.; SANTOS, A. R.; VINCE, C. C.; MARCHI, F. A.; KREPISCHI, A. C.; LAPA, R. M.; ZAMPERLINI, G.; CRISTOFANI, L. M.; NOVAK, E. M.
  • article 13 Citação(ões) na Scopus
    Haploidentical bone marrow transplantation with post transplant cyclophosphamide for patients with X-linked adrenoleukodystrophy: a suitable choice in an urgent situation
    (2018) FERNANDES, Juliana Folloni; BONFIM, Carmem; KERBAUY, Fabio Rodrigues; RODRIGUES, Morgani; ESTEVES, Iracema; SILVA, Nathalia Halley; AZAMBUJA, Alessandra Prandini; MANTOVANI, Luiz Fernando; KUTNER, Jose Mauro; LOTH, Gisele; KUWAHARA, Cilmara Cristina; BUENO, Clarissa; KONDO, Andrea Tiemi; RIBEIRO, Andreza Alice Feitosa; KOK, Fernando; HAMERSCHLAK, Nelson
    Allogeneic hematopoietic stem cell transplantation (HSCT) is the only treatment that enhances survival and stabilizes neurologic symptoms in X-linked adrenoleukodystrophy (X-ALD) with cerebral involvement, a severe demyelinating disease of childhood. Patients with X-ALD who lack a well-matched HLA donor need a rapid alternative. Haploidentical HSCT using post transplant cyclophosphamide (PT/Cy) has been performed in patients with malignant and nonmalignant diseases showing similar outcomes compared to other alternative sources. We describe the outcomes of transplants performed for nine X-ALD patients using haploidentical donors and PT/Cy. Patients received conditioning regimen with fludarabine 150 mg/m(2) , cyclophosphamide 29 mg/kg and 2 Gy total body irradiation (TBI) with or without antithymocyte globulin. Graft-vs.-host disease prophylaxis consisted of cyclophosphamide 50 mg/kg/day on days +3 and +4, tacrolimus or cyclosporine A and mycophenolate mofetil. One patient had a primary graft failure and was not eligible for a second transplant. Three patients had secondary graft failure and were successfully rescued with second haploidentical transplants. Trying to improve engraftment, conditioning regimen was changed, substituting 2 Gy TBI for 4 Gy total lymphoid irradiation. Eight patients are alive and engrafted (17-37 months after transplant). Haploidentical HSCT with PT/Cy is a feasible alternative for X-ALD patients lacking a suitable matched donor. Graft failure has to be addressed in further studies.
  • article 10 Citação(ões) na Scopus
    BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma
    (2016) NOVAK, E. M.; HALLEY, N. S.; GIMENEZ, T. M.; RANGEL-SANTOS, A.; AZAMBUJA, A. M. P.; BRUMATTI, M.; PEREIRA, P. L.; VINCE, C. S. C.; GIORGI, R. R.; BENDITE, I.; CRISTOFANI, L. M.; ODONE-FILHO, V.
    Neuroblastoma (NB) is the most common extra cranial solid tumor of childhood and often lethal in childhood. Clinical and biologic characteristics that are independently prognostic of outcome in NB are currently used for risk stratification to optimally the therapy. It includes age at diagnosis, International Neuroblastoma Staging System tumor histopathology and MYCN amplification. However, even in patients with theoretically good prognosis, such as localized tumor and non amplified MYCN, either disease progress or recurrence may occur. Potential genetic determinants of this unfavorable behavior are not yet fully clarified. The presence of elevated expression of AHCY, PKMYT1, and BLM has accompanied poor prognosis MYCN-amplified neuroblastoma patients. Considering the potential implication of these genes on the clinical management of NB, we hypothesize that the identification-of genetic variations may have significant impact during development of the recurrent or progressive disease. Using targeted DNA sequencing, we analyzed the mutation profiles of the genes PKMYT1, AHCY, and BLM in tumor samples of five patients with MYCN amplified and 15 MYCN non-amplified NB. In our study, BLM germline variants were detected in two patients with MYCN-non-amplified neuroblastoma. Our data allow us to hypothesize that, regardless of MYCN status, these mutations partially abolish BLM protein activity by impairing its ATPase and helicase activities. BLM mutations are also clinically relevant because BLM plays an important role in DNA damage repair and the maintenance of genomic integrity. We also found a novel variant in our cohort, PKMYT1 mutation localized in the C-terminal domain with effect unknown on NB. We hypothesize that this variant may affect the catalytic activity of PKMYT1 in NB, specifically when CDK1 is complexed to cyclins. The prognostic value of this mutation must be further investigated. Another mutation identified was a nonsynonymous variant in AHCY. This variant may be related to the slow progression of the disease, even in more aggressive cases. It affects the maintenance of the catalytic capacity of AHCY, leading to the consequent functional effects observed in the NB patients studied. In conclusion, our hypothesis may provide that mutations in BLM, AHCY and PKMYT1 genes found in children with MYCN-amplified or MYCN-non amplified neuroblastomas, may be associated with the prognosis of the disease.
  • conferenceObject
    CD8 Positive T Cell Number as Indicator of Prognosis in Children with Relapsed or Primarily Refractory Cancer
    (2018) ODONE-FILHO, V.; CRISTOFANI, L. M.; TEIXEIRA, R. A.; GIMENEZ, T. M.; SANTOS, A. R.; MARCHI, F. A.; LAPA, R. L.; KREPISCHI, A. C.; NOVAK, L. M.; BRUMATTI, M.; PEREIRA, P. L.; AZAMBUJA, A. M.; DORIA-FILHO, U.; CORNACHIONNI, A. L.; VINCE, C. S.; NEVES, N. H.
  • conferenceObject
    Blinatumomab (BLINA) as Sole Therapy for Relapsed Acute Leukemia (ALL) after Allogenic Hematopoietic Stem Cell Transplantation (HSCT)
    (2020) PEREIRA, P.; VINCE, C.; BRUMATTI, M.; HALLEY, N.; AZAMBUJA, A.; FERNANDES, J.; HAMERSCHLAK, N.; ZAMPERLINI-NETTO, G.; PEREIRA, A.; KROHLING, D.; ODONE-FILHO, V.
  • conferenceObject
    Hydroxyurea (HU) Therapy for Patients With Post-Transplant Lymphoproliferative Disease (PTLD): Treatment and Prevention of New Episodes
    (2020) PEREIRA, P.; VINCE, C.; AZAMBUJA, A.; BRUMATTI, M.; CRISTOFANI, L.; HALLEY, N.; PEREIRA, A.; ZAMPERLINI-NETTO, G.; GUEDES, G.; ODONE-FILHO, V.